154 related articles for article (PubMed ID: 16168710)
1. Targeted therapy comes of age in scleroderma.
Denton CP; Black CM
Trends Immunol; 2005 Nov; 26(11):596-602. PubMed ID: 16168710
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targets in systemic sclerosis.
Denton CP
Arthritis Res Ther; 2007; 9 Suppl 2(Suppl 2):S6. PubMed ID: 17767744
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and consequences of fibrosis in systemic sclerosis.
Denton CP; Black CM; Abraham DJ
Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673
[TBL] [Abstract][Full Text] [Related]
4. Innovative therapies for systemic sclerosis.
Ong VH; Denton CP
Curr Opin Rheumatol; 2010 May; 22(3):264-72. PubMed ID: 20190640
[TBL] [Abstract][Full Text] [Related]
5. Scleroderma--clinical and pathological advances.
Denton CP; Black CM
Best Pract Res Clin Rheumatol; 2004 Jun; 18(3):271-90. PubMed ID: 15158741
[TBL] [Abstract][Full Text] [Related]
6. The immunobiology of systemic sclerosis.
Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis.
Badea I; Taylor M; Rosenberg A; Foldvari M
Rheumatology (Oxford); 2009 Mar; 48(3):213-21. PubMed ID: 19022832
[TBL] [Abstract][Full Text] [Related]
8. Future targets in the management of systemic sclerosis.
Tyndall A; Matucci-Cerinic M; Müller-Ladner U
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii49-53. PubMed ID: 19487225
[TBL] [Abstract][Full Text] [Related]
9. Innovative antifibrotic therapies in systemic sclerosis.
Beyer C; Distler O; Distler JH
Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
[TBL] [Abstract][Full Text] [Related]
10. [Systemic sclerosis--introductory lecture].
Kaliterna DM; Radić M
Reumatizam; 2010; 57(2):90-3. PubMed ID: 21875010
[TBL] [Abstract][Full Text] [Related]
11. Scleroderma: from cell and molecular mechanisms to disease models.
Abraham DJ; Varga J
Trends Immunol; 2005 Nov; 26(11):587-95. PubMed ID: 16168711
[TBL] [Abstract][Full Text] [Related]
12. Immunological basis of systemic sclerosis.
Zuber JP; Spertini F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii23-5. PubMed ID: 16987826
[TBL] [Abstract][Full Text] [Related]
13. [An update on systemic sclerosis].
Kowal-Bielecka O
Ann Acad Med Stetin; 2010; 56 Suppl 1():80-2. PubMed ID: 21365948
[TBL] [Abstract][Full Text] [Related]
14. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events.
Chizzolini C
Ann Med; 2007; 39(1):42-53. PubMed ID: 17364450
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways as novel therapeutic targets in systemic sclerosis.
Trojanowska M; Varga J
Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
[TBL] [Abstract][Full Text] [Related]
16. Vascular complications of scleroderma.
Guiducci S; Giacomelli R; Cerinic MM
Autoimmun Rev; 2007 Sep; 6(8):520-3. PubMed ID: 17854742
[TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
18. Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma?
Coelho LF; de Oliveira JG; Kroon EG
Immunol Lett; 2008 Jun; 118(2):110-5. PubMed ID: 18499269
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies for systemic sclerosis.
Denton CP; Ong VH
Nat Rev Rheumatol; 2013 Aug; 9(8):451-64. PubMed ID: 23567456
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenic mechanisms in systemic sclerosis and their therapeutical consequences. Part 2: treatment].
Zuber JP; Chizzolini C; Leimgruber A; Bart PA; Spertini F
Rev Med Suisse; 2006 Apr; 2(62):1058, 1060-6. PubMed ID: 16711151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
